Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2026 Q1 | Apr 30, 2026 | Arquitos Capital Management | -7.2% | -7.2% | ENDI, FNCH, LQDA | activism, Biotechnology, liquidation, Patent litigation, SmallCap, special situations, value | LQDA FNCH ENDI |
View | |
| 2025 Q3 | Oct 20, 2025 | Arquitos Capital Management | 29.6% | 66.8% | ENDI, FNCH, LQDA | Biotechnology, FDA, Litigation, Patents, small caps, special situations, value | Portfolio heavily concentrated in biotech companies with significant patent litigation and FDA approval catalysts. Liquidia received FDA approval for Yutrepia and launched successfully, while Finch won patent infringement case against Ferring with potential for enhanced damages. | FNCH ENDI LQDA |
View |
| 2025 Q4 | Jan 22, 2026 | Arquitos Capital Management | 0.0% | 0.0% | ENDI, FNCH, LQDA, MRK, UTHR | Biotechnology, Concentration, Patents, SmallCap, special situations, value | Portfolio concentrated in biotech companies including Liquidia Corporation with successful drug launch capturing 25% market share, Finch Therapeutics with patent litigation victory, and focus on companies with unique drug delivery technologies and patent protection. Merck identified as logical buyer for Liquidia given their ownership of complementary drug Winrevair and active M&A strategy. Combination therapy potential creates strategic value for potential acquirers. | FNCH ENDI LQDA |
View |
| 2024 Q4 | Jan 26, 2025 | Arquitos Capital Management | - | 29.6% | ENDI, FNCH, LQDA, MSTR, NTPIF, UTHR | Biotechnology, concentrated, FDA approval, Patent litigation, Pharmaceuticals, small caps | Two major biotech positions dominate the portfolio. Finch Therapeutics won a patent infringement case against Ferring with potential for enhanced damages up to 3x the $30M jury award. Liquidia Therapeutics awaits FDA approval in May 2025 for its inhaler product Yutrepia, which could capture 80-90% market share due to superior delivery technology. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Fund Letters | Arquitos Capital Management | Finch Therapeutics | Biotechnology | Biotechnology | Bull | NASDAQ | asset monetization, biotechnology, Chapter 11, IP Portfolio, Liquidation, Patent Litigation, Special Situation | View Pitch |
| Jan 24, 2026 | Fund Letters | Steven L. Kiel | Finch Therapeutics Group, Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, Legal, litigation, patents, royalties | View Pitch |
| Nov 29, 2025 | Fund Letters | Steven L. Kiel | Finch Therapeutics Group, Inc. | Health Care | Biotechnology | Bull | Dubai Financial Market | Asymmetry, Catalyst, damages, litigation, royalties, Timing, Willful-infringement | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||